Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,681 to 1,700 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets. | Front Oncol | 2021 | 35145909 | PubTator, text mining | PubMed |
| Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. | Front Oncol | 2021 | 35127473 | PubTator, text mining | PubMed |
| EFNA3 Is a Prognostic Biomarker Correlated With Immune Cell Infiltration and Immune Checkpoints in Gastric Cancer. | Front Genet | 2021 | 35126464 | PubTator, text mining | PubMed |
| The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. | Nat Cancer | 2021 | 35121907 | PubTator, text mining | PubMed |
| Immunotherapy and radiation for high-grade glioma: a narrative review. | Transl Cancer Res | 2021 | 35116570 | PubTator, text mining | PubMed |
| Communication Pattern Changes Along With Declined IGF1 of Immune Cells in COVID-19 Patients During Disease Progression. | Front Immunol | 2021 | 35095832 | PubTator, text mining | PubMed |
| CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. | Front Oncol | 2021 | 35083154 | PubTator, text mining | PubMed |
| Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma. | Front Mol Biosci | 2021 | 35071320 | PubTator, text mining | PubMed |
| A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. | Front Oncol | 2021 | 35070967 | PubTator, text mining | PubMed |
| The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. | Transl Lung Cancer Res | 2021 | 35070764 | PubTator, text mining | PubMed |
| Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. | Transl Lung Cancer Res | 2021 | 35070752 | PubTator, text mining | PubMed |
| Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma. | Front Immunol | 2021 | 35069553 | PubTator, text mining | PubMed |
| SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis. | Front Genet | 2021 | 35058967 | PubTator, text mining | PubMed |
| Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. | Life (Basel) | 2021 | 35054417 | PubTator, text mining | PubMed |
| Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection. | Biomolecules | 2021 | 35053187 | PubTator, text mining | PubMed |
| The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now? | Biomedicines | 2021 | 35052770 | PubTator, text mining | PubMed |
| Case Report: Autoimmune Lymphoproliferative Syndrome vs. Chronic Active Epstein-Barr Virus Infection in Children: A Diagnostic Challenge. | Front Pediatr | 2021 | 35036396 | PubTator, text mining | PubMed |
| Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing. | Cells | 2021 | 35011583 | PubTator, text mining | PubMed |
| B Lineage Cells in ANCA-Associated Vasculitis. | Int J Mol Sci | 2021 | 35008813 | PubTator, text mining | PubMed |
| The ABCs of Antigen Presentation by Stromal Non-Professional Antigen-Presenting Cells. | Int J Mol Sci | 2021 | 35008560 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=85